Indaptus reports FY2023 loss of $1.83/sh; cash $13.4M; Phase 1 Decoy20 advancing

Indaptus Therapeutics, Inc.

FY2023 net loss per share $1.83 vs $1.73 in FY2022; cash at Dec 31, 2023 was $13.4M (down from $26.4M).
Cash runway expected through Q3 2024; excludes $0.3M ATM proceeds in March 2024.
Positive results from second cohort of Phase 1 Decoy20 trial; initiating multi-dose in solid tumors.
European patent approved in Jan 2024 for platform technology covering viral infection composition.
R&D expenses rose 21% YoY to $7.6M driven by Phase 1 trial and pipeline expansion.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.